Hiltonol injection for prostate cancer on active surveillance
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a drug called Hiltonol (Poly-ICLC) given directly into the prostate tumor along with an injection under the skin. It is for men with low-risk prostate cancer who are on active surveillance, to see if the drug can slow or stop the cancer from growing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have low-grade prostate cancer (Gleason 3+3 or 3+4) and be a candidate for active surveillance.
- You must be willing to have an injection of the study drug directly into your prostate tumor.
- You must not have had any prior cancer treatment for prostate cancer (like surgery, radiation, or hormone therapy).
- You must not have active infections or conditions that increase the risk of infection from the injection.
- You must have adequate kidney, liver, and blood cell function as shown by lab tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new imaging test called rhPSMA-7.3 (18F) PET/CT to see if it can better detect prostate cancer in men who are on active surveillance because their cancer is considered low-risk or favorable intermediate-risk. You would also get an MRI and a biopsy as part of the study.
This study tests an experimental vaccine that may help your immune system fight prostate cancer cells. If you have low- or intermediate-risk prostate cancer and are under active surveillance, this vaccine might slow or prevent the cancer from growing.
This trial tests a radioactive drug called Lu 177 JH020002 for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. The drug targets a protein on cancer cells to deliver radiation directly, possibly slowing the disease.
This trial tests whether a combination of three new drugs (SHR3680, HS-20093, and SHR2554) can help slow or stop prostate cancer growth. It is for men who are already on hormone therapy and whose PSA level is still rising.
This trial tests a new imaging injection (INR101) to help find where prostate cancer may have returned after your first treatment. It uses PET/CT scans to spot cancer cells more clearly.
This trial tests an injection called STM-416p given during prostate removal surgery to see if it can help prevent prostate cancer from coming back. It may be an option for men with intermediate to high-risk prostate cancer who are already planning to have their prostate removed.
Hear when a new Prostate Cancer Patients on Active Surveillance trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.